[1] Among his most significant scientific achievements to date are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers, the identification of the molecular mechanisms of several drugs, and the discovery of fundamental organization principles of the proteome and the lipidome of higher organisms, as well as the characterization of molecular components relevant for innate immunity.

His work has directly contributed to a systems-level understanding of pathogen infections in host cells and of the mechanism of action of specific drugs.

[3][4] In June 2017, was awarded the title of Commendatore (Commander) dell'Ordine al Merito della Repubblica Italiana (Order of Merit of the Italian Republic) by HE Giorgio Marrapodi, Ambassador of Italy.

[8][9] In 2021 he also became the academic coordinator of the Innovative Medicines Initiative REsolution project, which focus on the annotation and experiment study of SLC genetic variants.

The article "Functional organization of the yeast proteome by systematic analysis of protein complexes" by Gavin, AC*, 36 authors, Superti-Furga G* (* shared correspondence), Nature 2002 [21] has been cited almost 6,000 times.

As scientific director of CeMM, Giulio Superti-Furga promoted a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts.

Recent research interests of Giulio Superti-Furga include novel ways to create functional personalized medicine approaches and understanding the role of the human membrane transporters in pathophysiology and drug discovery.

[28] Also his laboratory contributed to elucidate the role of SLC38A9 in the mechanism by which the cell recognizes the presence of amino acids and thereby controls mTOR activity.

In collaboration with the Medical University of Vienna, Giulio developed a technique called “Pharmacoscopy” to screen primary patient material using automated confocal microscopy and quantify single-cell events such as differential cell death, protein expression, cell morphology – creating robust and unique data sets.

[39] In 2018, driven by the interest in identifying underlying genetic determinants of drug response in a specific type of cancer of the haematopoietic system, his lab reported on the mechanistic link between RAS and the LZTR1 gene, previously associated with a variety of rare disorders.

The laboratory developed a small molecule interaction mapping technology using mass spectrometric thermal stability shifts at the proteome-wide level.

Recently, his lab determined by biochemistry and mass spectrometry the molecular interactions that involved SLC15A4, which led to the identification of an uncharacterized protein CXorf21 (named TASL).

[49][50] Giulio Superti-Furga is interested in many aspects of science, from hard-core biochemistry and molecular biology to the processes leading to innovation and creativity of whole communities.

[52] Later in 2010, Giulio Superti-Furga co-founded the biotechnology company Haplogen GmbH in Vienna, a CeMM spin-off focused on haploid genetics.

Haplogen Genomics together with CeMM released in 2013 the world's largest collection of engineered human haploid knockout cell lines for biomedical discovery.